BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024

Reuters

14 Jan

BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024

Jan 14 (Reuters) - Charles River Laboratories International Inc CRL.N:

CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 REVENUE WILL DECLINE ORGANICALLY IN A SIMILAR RANGE AS ESTIMATED IN 2024
CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 NON-GAAP OPERATING MARGIN WILL BE MODESTLY BELOW ESTIMATED 2024 LEVEL
CHARLES RIVER LABORATORIES INTERNATIONAL INC: DSA PRICING EXPECTED TO BE A HEADWIND TO REVENUE FOR 2025
CHARLES RIVER LABORATORIES : LOWER COMMERCIAL CDMO REVENUE EXPECTED TO REDUCE CONSOLIDATED REVENUE GROWTH BY ABOUT 1% IN 2025
CHARLES RIVER LABORATORIES : ONGOING SITE CONSOLIDATION ACTIONS WILL RESULT IN A REVENUE HEADWIND OF ABOUT 0.5% IN 2025
CHARLES RIVER : AS RESULT OF CDMO BUSINESS CHALLENGES, ASSESSING THE RECOVERABILITY OF GOODWILL AND LONG-LIVED ASSETS FOR POTENTIAL IMPAIRMENT

Further company coverage: CRL.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503520205"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503520205\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503520205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503520205","market":"us","top_or_hot":-1,"title":"BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024</title></head><body><p><span>Jan 14 (Reuters)</span><span> - </span>Charles River Laboratories International Inc <span>CRL.N</span>:</p><ul><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 REVENUE WILL DECLINE ORGANICALLY IN A SIMILAR RANGE AS ESTIMATED IN 2024</p></li><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 NON-GAAP OPERATING MARGIN WILL BE MODESTLY BELOW ESTIMATED 2024 LEVEL</p></li><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC: DSA PRICING EXPECTED TO BE A HEADWIND TO REVENUE FOR 2025</p></li><li><p>CHARLES RIVER LABORATORIES : LOWER COMMERCIAL CDMO REVENUE EXPECTED TO REDUCE CONSOLIDATED REVENUE GROWTH BY ABOUT 1% IN 2025</p></li><li><p>CHARLES RIVER LABORATORIES : ONGOING SITE CONSOLIDATION ACTIONS WILL RESULT IN A REVENUE HEADWIND OF ABOUT 0.5% IN 2025</p></li><li><p>CHARLES RIVER : AS RESULT OF CDMO BUSINESS CHALLENGES, ASSESSING THE RECOVERABILITY OF GOODWILL AND LONG-LIVED ASSETS FOR POTENTIAL IMPAIRMENT</p></li></ul><p>Further company coverage: <span>CRL.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-14 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024</title></head><body><p><span>Jan 14 (Reuters)</span><span> - </span>Charles River Laboratories International Inc <span>CRL.N</span>:</p><ul><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 REVENUE WILL DECLINE ORGANICALLY IN A SIMILAR RANGE AS ESTIMATED IN 2024</p></li><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 NON-GAAP OPERATING MARGIN WILL BE MODESTLY BELOW ESTIMATED 2024 LEVEL</p></li><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC: DSA PRICING EXPECTED TO BE A HEADWIND TO REVENUE FOR 2025</p></li><li><p>CHARLES RIVER LABORATORIES : LOWER COMMERCIAL CDMO REVENUE EXPECTED TO REDUCE CONSOLIDATED REVENUE GROWTH BY ABOUT 1% IN 2025</p></li><li><p>CHARLES RIVER LABORATORIES : ONGOING SITE CONSOLIDATION ACTIONS WILL RESULT IN A REVENUE HEADWIND OF ABOUT 0.5% IN 2025</p></li><li><p>CHARLES RIVER : AS RESULT OF CDMO BUSINESS CHALLENGES, ASSESSING THE RECOVERABILITY OF GOODWILL AND LONG-LIVED ASSETS FOR POTENTIAL IMPAIRMENT</p></li></ul><p>Further company coverage: <span>CRL.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRL","symbol_name":"查尔斯河","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nFWN3OA0AV:1","article_id":"2503520205","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503520205","pubTimestamp":1736860683,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024Jan 14  - Charles River Laboratories International Inc CRL.N:CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 REVENUE WILL DECLINE ORGANICALLY IN A SIMILAR RANGE AS ESTIMATED IN 2024CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 NON-GAAP OPERATING MARGIN WILL BE MODESTLY BELOW ESTIMATED 2024 LEVELCHARLES RIVER LABORATORIES INTERNATIONAL INC: DSA PRICING EXPECTED TO BE A HEADWIND TO REVENUE FOR 2025CHARLES RIVER LABORATORIES : LOWER COMMERCIAL CDMO REVENUE EXPECTED TO REDUCE CONSOLIDATED REVENUE GROWTH BY ABOUT 1% IN 2025CHARLES RIVER LABORATORIES : ONGOING SITE CONSOLIDATION ACTIONS WILL RESULT IN A REVENUE HEADWIND OF ABOUT 0.5% IN 2025CHARLES RIVER : AS RESULT OF CDMO BUSINESS CHALLENGES, ASSESSING THE RECOVERABILITY OF GOODWILL AND LONG-LIVED ASSETS FOR POTENTIAL IMPAIRMENTFurther company coverage: CRL.N ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CRL":"查尔斯河"},"translate_title":"简介-Charles River Laboratories International预计2025年收入将在与2024年估计相似的范围内有机下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":0.9},"content_text":"BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024Jan 14 (Reuters) - Charles River Laboratories International Inc CRL.N:CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 REVENUE WILL DECLINE ORGANICALLY IN A SIMILAR RANGE AS ESTIMATED IN 2024CHARLES RIVER LABORATORIES INTERNATIONAL INC: EXPECT 2025 NON-GAAP OPERATING MARGIN WILL BE MODESTLY BELOW ESTIMATED 2024 LEVELCHARLES RIVER LABORATORIES INTERNATIONAL INC: DSA PRICING EXPECTED TO BE A HEADWIND TO REVENUE FOR 2025CHARLES RIVER LABORATORIES : LOWER COMMERCIAL CDMO REVENUE EXPECTED TO REDUCE CONSOLIDATED REVENUE GROWTH BY ABOUT 1% IN 2025CHARLES RIVER LABORATORIES : ONGOING SITE CONSOLIDATION ACTIONS WILL RESULT IN A REVENUE HEADWIND OF ABOUT 0.5% IN 2025CHARLES RIVER : AS RESULT OF CDMO BUSINESS CHALLENGES, ASSESSING THE RECOVERABILITY OF GOODWILL AND LONG-LIVED ASSETS FOR POTENTIAL IMPAIRMENTFurther company coverage: CRL.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}